The US government and industry have a unique opportunity to forge a strong partnership that helps build capabilities for rapid response to unknown and rare biological threats, be they natural or man-made. After the Ebola outbreaks the entire global health community began to discuss how we could be more prepared for an outbreak of pandemic potential or Disease X. I think everyone agrees that we cannot make a vaccine, therapeutic and diagnostic for every known threat, much less expect to have products for the unknown. This means we as a nation must invest in technologies with flexibility and speed. For companies that are investing in these technologies, the possibilities for their use are broad and commercially significant. How, then, does the US government partner with industry to ensure the viability of and later access to these technologies for the benefit of our shared health security? What policies can government and industry put forward to build strong partnerships based on mutual understanding of the goals of the public and private sectors? How do we need to change the business model for working with rapid platform technologies versus other modalities, if at all?
Acting Assistant Commissioner for Counterterrorism Policy and Acting Director of the Office of Counterterrorism and Emerging Threats, Office of the Chief Scientist
U.S. Food and Drug Administration (FDA)
Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, Office of the Undersecretary of Defense for Policy
Countering Weapons of Mass Destruction, Office of the Undersecretary of Defense for Policy (DASD/C-WMD)